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Use of cotrimoxazole prophylaxis in HIV infected in patients at a
referral hospital
S KHOZA, V MKUDU, J MTHETHWA, R BULAYA-TEMBO, CFB NHACHI
Abstract
Objective: To assess the extent o f use o f cotrimoxazole prophylaxis in the prevention o f opportunistic 
infections in HIV infected patients.
Setting'. Parirenyatwa Hospital, a major referral and teaching hospital.
Design: A retrospective study:
Subjects. 234 HIV infected patients admitted between January and June 2004, with a history o f symptoms 
falling into the WHO stage 3 AIDS, were included.
Main Outcome Measures: Cotrimoxazole prophylaxis, PCP prevalence, andmortality.
Results: 234 patients' records were reviewed and 19% of the patients had received cotrimoxazole 
prophylaxis. PCP prevalence was 36% which was diagnosed mainly by clinical examination and sometimes
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with the additional help o f chest X-rays. O f those who were on prophylaxis, 75% were on primary 
prophylaxis and the rest on secondary prophylaxis. All patients on prophylaxis were using cotrimoxazole, 
with the 960mg once daily dosing being the most common regimen (96%). Receiving prophylaxis was 
associated with being female (p=0.0067), widowed (p=0.012), and taking ARV therapy (p=0.0026). 
Prophylaxis significantly reduced mortality (p=0.0017). The development o f PCP was associated with a 
history o f tuberculosis relapse (p=0.022).
Conclusion: Cotrimoxazole prophylaxis is important in reducing hospital admissions due to opportunistic 
infections and increasing survival especially in areas with limited access to antiretroviral therapy.
Introduction
The sub-Saharan region is the most affected by the 
HIV/AIDS pandemic with an average o f 8% of the 
population being infected.1 Opportunistic infections 
have a major impact on the health and survival o f HIV 
infected patients. The advent o f highly active anti­
retroviral therapy has, however, significantly reduced 
the prevalence o f opportunistic infections in HIV 
infected patients.
Primary prophylaxis o f opportunistic infections 
continues to be one o f the most important strategies in 
the management o f patients infected with HIV.2 In 
addition, primary prophylaxis against opportunistic 
infections including Pneumocystis carinni pneumonia 
(PCP) has already been shown to have an independent 
role in prolonging survival.3,4 Pneumocystis carinii 
remains an important pathogen for the broad spectrum 
o f  im m unocom prom ised  ind iv iduals , desp ite  
significant advances in antim icrobial therapy. 
Cotrimoxazole is recommended as the drug o f choice 
for the prevention and treatment of PCP.2'5
In Zimbabwe, PCP has been reported to be one o f the 
m ost com m on life -th rea ten in g  oppo rtun is tic  
infections, occurring in 33% of HIV positive people.6 
Its significant contribution to the high mortality and 
morbidity rate makes it very critical to the clinician 
who is concerned about improving survival in this 
group o f patients. The World Health Organisation 
(WHO) and the Essential Drugs List of Zimbabwe 
(EDLIZ) recommends that cotrimoxazole should be 
given to all patients with symptomatic HIV (and not on 
antiretroviral therapy), or who have had an attack of 
PCP, and to all patients who have any AIDS defining 
condition. The regimen recommended is a life-long, 
960mg (sulphamethoxazole 800mg and 160mg 
trimethoprim) once daily dosing.
In resource-poor settings where accessibility and 
affordability of ARV therapy are major stumbling 
blocks to the provision of highly active antiretroviral 
therapy (HAART), prophylaxis against opportunistic 
infections may be the next best alternative in the 
m anagement o f HIV and AIDS. The use o f 
cotrimoxazole prophylaxis is associated with a 
significant decrease in the incidence o f opportunistic 
infections, notably streptococcus pneumoniae 
pneumonia, PCP, non-typhoid salmonelloses, non­
specific gastroenteritis, cerebral toxoplasmosis, 
pneumococcal pneumonia, bacteria dermatoses, acute 
unexplained fevers, nocardiosis, isosporiasis and
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malaria.7 The study seeks to assess the extent o f the use 
o f cotrimoxazole prophylaxis in HIV infected patients 
admitted at a major referral hospital.
Materials and Methods
The study was carried out at Parirenyatwa Hospital, a 
major referral and teaching hospital in Harare, 
Zimbabwe. Medical records o f HIV infected patients 
admitted into the medical wards during the period 1 
January to 30 June 2004 were reviewed. Patients 
above the age o f 18 with a medical history falling into 
the WHO stage 3 AIDS category were recruited into the 
study. The inclusion criteria was having a history o f one 
or more o f the following: unexplained fever or 
diarrhoea o f  more than four weeks duration, 
oropharyngeal candidiasis, hairy leukoplakia, more 
than 10% weight loss, pulmonary TB, PCP, CD4 cell 
count less than 200/ml, bedridden for more than 50% of 
a day and a documented positive HIV test. Ethical 
approval was obtained from the hospital Ethics Review 
Committee.
A computer print out was used to retrieve patient 
medical records. A structured collection tool was then 
used  to ex trac t data on socio -dem ograph ic  
characteristics and medical history including a history 
o f prophylaxis. Cotrimoxazole prophylaxis was 
defined as receiving the drug continuously for at least 
one month.
Statistical analysis was performed using STATA 7.0, 
Texas USA. After checking for normality o f the data, 
the variables age and number o f admissions were noted 
to be normally distributed. The mean (SD) and median 
(Q„ Q3) were used to describe normally and non- 
normally distributed variables respectively. The 
student's t-test and the Mann-Whitney test were used 
where appropriate to compare the distribution of 
variables between groups. The 0.05 level o f 
significance was used.
Results
Four hundred and three medical records were 
reviewed, o f which 234 (58%) had complete 
information and were therefore included in the study. 
Table I shows the characteristics o f patients grouped 
according to whether they received prophylaxis or not 
and history of PCP infection as determined by the 
medical history. Table I
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Table I: Characteristics o f study participants. Values are numbers (percentages) unless stated otherwise.
C h a ra c te r is t ic O v e ra ll (n= 234) O n  P ro p h y la x is  
(n= 51)
N o t on  P ro p h y la x is  p  v a lu e  
(n=183)
Sex, M ales 1 0 8 (4 6 ) 15 (29) 93 (51) 0.0067
A ge (m ean, SD ) years 37.8 (9.8) 3 7 .2 (1 0 .5 ) 38.0  (9.7) 0.5993
E m ployed 99 (42) 17 (3 3 ) 82 (45) 0.1415
M a rita l
Single 2 6 (1 1 ) 6 (1 2 ) 2 0 (1 1 ) 0.012
D ivorced 4 2 (1 8 ) 1 0 (2 0 ) 3 2 (1 8 )
W indow ed 3 6 (1 5 ) 15 (2 9 ) 2 1 (1 2 )
M arried 130 (56) 20  (39) 110 (6 0 )
Patients on ARV therapy 1 8 (8 ) 9 (1 8 ) 9 ( 5 ) 0.0026
Pneum ocystis carin ii 85 (36) 1 8 (3 5 ) 67 (37) 0 .8644
M ortality 85 (36) 9 (1 7 ) 76 (42) 0.0017
N u m b er o f  adm issions (m ean  SD) 1 .4 (0 .7 4 ) 1.3 (0.17) 1.4 (0.75) 0 .5824
A verage duration  stay  p e r 6 .0  (3,12) 6 .0  (3,12) 6 .0 (3,12) 0 .7089
A dm ission  (m edian; Q l5 Q 3) days
O th e r opportun istic  infections 89 (38) 2 6 (5 1 ) 63 (34) 0.3563
Out o f 216 patients 42 (19%) who were not on history o f TB relapse. However, treatment o f the
an tiretrov iral therapy received  cotrim oxazole respiratory infections which preceded PCP was
prophylaxis. The commonest regimen was 960mg once 
a day (96%), and the rest were on 480mg two times a 
day. A small proportion o f patients (8%) were on 
antiretroviral therapy.
More than half (58%) of the patients were not 
formally employed and 56% were married. The main 
qualifying criteria for prophylaxis were a history of 
tuberculosis (25%), recurrent respiratory infections 
(16%) and PCP (13%). Others qualified on the 
following criteria: chronic diarrhoea (14), recurrent 
candidiasis (8), Kaposis' sarcoma (4), meningitis (8), 
weight loss greater than 10% (9), unexplained fever for 
longer than four weeks (2), and cytomegalovirus 
infection (1). O f the patients not on cotrimoxazole 
prophylaxis and not on antiretroviral therapy (n=183), 
5% were allergic to cotrimoxazole. The prevalence of 
all the opportunistic infections was 38%, while a 36% 
prevalence of PCP was also recorded.
Prophylaxis was associated with being female 
(p=0.0067), widowed (p=0.012) and receiving ARV 
therapy (p=0.0026). In addition, prophylaxis was 
found to significantly reduce the risk o f mortality 
(p=0.0017).
A significantly high rate of co-infection was recorded 
in patients who had PCP with 48% having TB and 12% 
with other forms of pneumonia. Co-infections were 
successfully treated in 67% of the patients. Antibiotic 
treatment for PCP included cotrimoxazole (81 %) and 
clindamycin (19%).
O f patients who developed PCP 39% had a past 
history o f other respiratory infections especially TB 
(35%). Statistical analysis further revealed a strong 
association (p=0.022) between PCP infection and a
successful in almost all the patients (91 %). On the other 
hand, patients who did not get PCP had a 71% 
prevalence o f other respiratory infections. The most 
common being TB (85%) followed by bacterial 
pneumonia (15%). Most (72%) o f these were 
successfully treated.
A mortality rate of 36% was recorded with the major 
cause of death being PCP followed by TB and 
meningitis respectively. (Table II).
Table II: Major causes o f death, n=85.
C a u ses  o f  d e a th F re q u e n c y  %
PC P 27 32
Tuberculosis 18 21
M eningitis 11 13
B acteria l pneum onia 8 9
TB +  bacteria l p neum onia 9 11
K ap o s i’s sarcom a 4 5
O ther 8 10
Discussion
The study recorded a low use o f cotrimoxazole 
prophylaxis accompanied with a high mortality rate 
on patients not on prophylaxis. The PCP prevalence 
recorded (36%) is in agreement with that reported in 
an earlier study conducted nearly a decade ago.6 This 
possibly suggests that very little has changed in terms 
of therapeutic strategies in reducing opportunistic 
infections in HIV infected patients. The low number 
o f patients accessing antiretroviral therapy probably 
explains this observation.
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It is interesting to note that being on prophylaxis was 
associated with being female, widowed and being on 
antiretroviral therapy. Generally, females have a 
different health seeking behaviour in comparison to 
males. Females are known to be more health conscious, 
taking more responsibility for their health and that of 
family members. It is also natural that after the death of 
a spouse due to an AIDS related disease, the surviving 
partner will be more health conscious and therefore 
seek medical advice on preventing opportunistic 
infections. Even though a small number o f patients 
were on anti-retroviral therapy, it would appear as if  
constant contact o f the patient with the physician 
promotes the use o f prophylaxis. This is probably due 
to the fact that regular visits to the physician allow 
continuous and constant monitoring o f the patient's 
condition and hence better management.
A significant benefit o f cotrimoxazole prophylaxis in 
reducing mortality was not surprising, as this has been 
reported in clinical trials. The benefit in reducing PCP 
infection was also observed in this study even though 
this was not statistically significant. This is probably 
due to the small sample size studied, a low level o f 
compliance in those patients on prophylaxis and the use 
o f hospital subjects who by definition are o f  ill health in 
comparison to outpatients. In a meta-analysis o f 35 
randomised controlled trials involving 6 538 patients, 
cotrimoxazole prophylaxis was shown to be associated 
with a significant reduction in the incidence o f both 
PCP and toxoplasmosis.8
The strong association observed between the history 
of TB relapse and the development o f PCP is also not 
surprising. HIV infected patients in WHO stage 3 
already have a deteriorating immune system which 
makes them more likely to have TB relapses and other 
opportunistic infections. As stated in HIV treatment 
guidelines, cotrim oxazole prophylaxis is very 
important in this group of patients for preventing these 
opportunistic infections.
This was a retrospective study and hence prone to 
biases inherent in this design. The use o f patient 
medical records is associated with incomplete entries; 
however patient records that were deemed not to 
contain adequate information were excluded. In 
addition, this study was carried out in a hospital and 
used data collected from in patients. The use of hospital 
subjects may have introduced bias in estimating the 
extent o f cotrimoxazole prophylaxis. In patients, as 
earlier alluded to, are different from out patients in 
many respects. First, by definition in patients are o f  ill- 
health, and secondly the extent o f cotrimoxazole use 
could be different. Outpatients who visit the clinics 
regularly are more likely to be on cotrimoxazole 
prophylaxis and compliant. These patients are less 
likely to have opportunistic infections and therefore 
less likely to be admitted to a hospital. Conversely, as 
observed in this study in patients are likely not to be on 
prophylaxis or non-compliant. Therefore, these results 
cannot be generalised to outpatients and there is need 
for a follow up study to assess the use o f cotrimoxazole
prophylaxis in patients seen at the outpatients 
department.
The study underscores the importance o f 
cotrimoxazole prophylaxis in preventing opportunistic 
infections and reducing disease burden and mortality. 
Reduced opportunistic infections will result in a 
reduction in admissions. Health care resources spent in 
the treatment o f these opportunistic infections can then 
be redeployed to other departments that would 
ultimately result in improved health delivery services. 
The major causes o f death in this study were PCP and 
TB, which can be prevented by prophylaxis with 
c o tr im o x a z o le  and  is o n ia z id  re s p e c tiv e ly . 
Cotrimoxazole is cheap, widely available and the 
regimen of once a day dosing means compliance is not 
likely to be a problem.
Conclusion
Cotrimoxazole prophylaxis is important in reducing 
hospital admissions due to opportunistic infections and 
increasing survival especially in areas with limited 
access to antiretroviral therapy.
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